History teaching: documentary analysis of three public proposals in Bogotá (2004-2015)
5. Tres propuestas para enseñar historia en Bogotá
5.3. La Enseñanza de la Historia en el Ámbito Escolar
1 Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP for the initial treatment of patients with advanced-stage follicular
lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013; 31:1506-1513. PMID: 23530110
2 Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106:3725-3732. PMID: 16123223
3 Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP
chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin
Oncol. 2013; 31:314-320. PMID: 23233710
4 Marcus R, Imrie K, Solal-Celigny, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone
alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008; 26:4579-4586. PMID: 18662969
5 Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line
treatment for patients with indolent and mantel cell lymphomas: an open-label, multicenter, randomized, phase 3 non- inferiority trial. Lancet. 2013; 381:1203-1210. PMID: 23433739
6 Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with
relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008; 26:4473-4479. PMID: 18626004
7 Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with
follicular lymphoma with low tumor burden: clinical and molecular evaluation. Blood. 2001; 97:101-106. PMID: 11133748
8 IIIidge TM, Mayes S, Pettengell R, et al. Fractionated Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of
follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin
Oncol. 2014; 32:212-218. PMID: 24297953
9 Scholz CW, Pinto A, Linkesch W, et al. (90) Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30
months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013; 31: 308-313. PMID: 23233718
10 Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the
treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin
Oncol. 2013; 31: 565-572. PMID: 23295789
11 Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible
and active in indolent non-Hodgkin’s lymphoma. Br J Haematol. 2003; 123:271-277. PMID: 14531908
12 Petersen BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular
lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003; 21:5-15. PMID: 12506163
13 Horning SJ. Something old, something few, something subjective, and something déjà vu. J Clin Oncol. 2003; 21:1-2. PMID:
12506161
14 Rose AC, Shenoy PJ, Garrett G, et al. A systemic literature review and meta-analysis of radioimmunotherapy consolidation for
patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2012; 12:393-399. PMID: 23158095
51
17 Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-
treatment at progression in patients with indolent non-Hodgkin’s lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005; 23:1088-1095. PMID: 15657401
18 Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide,
mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104:3064-3071. PMID: 15284112
19 Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular
lymphoma. J Clin Oncol. 2005; 23:694-704. PMID: 15681517
20 Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory
indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2009; 27:5404-5409. PMID: 19805688
21 Leonard J, Sin-Ho J, Johnson J, et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus
rituximab in patients with recurrent follicular lymphoma. [Abstract 8000] J Clin Oncol.2012.
http://meetinglibrary.asco.org/content/93509-114.
22 Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with
relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014; 165:375-381. PMID: 24606326
23 Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan
radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002; 20:2453-2463. PMID: 12011122
24 Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma
significantly increases event-free survival and response duration compared with the standard weekly x4 schedule. Blood. 2004; 103:4416-4423. PMID: 14976046
25 McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with
rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000; 27:37-41. PMID: 11225999
26 McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent
lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005; 105:4573-4575. PMID: 15741224
27 Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone
prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG =1496 study. J
Clin Oncol. 2009; 27:1607-1614. PMID: 19522334
28 Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab
monotherapy: progress report and comparison with splenectomy. Oncologist. 2013; 18:190-197. PMID: 23345547
29 Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal
zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006; 107:125-135.
PMID: 16700034
30 Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-
stage follicular non-Hodgkin’s lymphoma: updated results after a median follow-up of 7.3 years from the International Randomized, Phase III First-Line Indolent Trial. J Clin Oncol. 2013; 31:1977-1983. PMID: 23547079
31 Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan
compared with no additional therapy after remission in advanced follicular lymphoma. J Clin Oncol. 2008; 26:5156-5164.
PMID: 18854568
32 Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med.
2005; 352:441-449. PMID: 15689582
33 Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J
Clin Oncl. 2005; 23:8018-8024. PMID: 16204012
34 Andriani A, Miedico A, Tedeschi L, et al. Management of long-term follow-up of early stage H. pylori-associated gastric MALT-
35 Economopoulos T, Dimopoulos MA, Mellou S, et al. Treatment of intermediate and high-grade non-Hodgkin’s lymphoma using CEOP versus CNOP. Eur J Haematol. 2002; 68:135-143. PMID: 12068793
36 Moccia AA, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in
diffuse large B-cell lymphoma for patients with a contraindication to anthracyclines. [Abstract 408]. ASH. 2009. Accessed:
http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/408.
37 Li Y, Yimamu M, Wang X, et al. Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-
germinal center immunophenotype diffuse large B-cell lymphoma cells with high Bcl-2 expression. Int J Hematol. 2014; 99:79- 86. PMID: 24258714
38 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Hodgkin’s Lymphomas. (V4.2014). Available at
53